AstraZeneca CEO Pascal Soriot said artificial intelligence is helping drugmakers develop medicines faster and make smarter…
Author: V3Media
Xsolis, Inc. Provides Notice of Data Security Incident
FRANKLIN, Tenn., June 5, 2026 /PRNewswire/ — Xsolis, Inc. (“Xsolis”), a vendor that provides case and…
Brayton Purcell LLP destaca los informes de KQED sobre el proyecto de ley federal que afecta las reclamaciones de silicosis por piedras artificiales
NOVATO, California, 5 de junio de 2026 /PRNewswire-HISPANIC PR WIRE/ — Brayton PurcellLLP está llamando la…
Cashless healthcare in India: Bridging operational gap between hospitals, TPAs, and insurers – Express Healthcare
Every day, across hospital admission counters in cities like Pune, Hyderabad, and Kolkata, a quiet crisis…
Dr Rajendra Pratap Gupta nominated by United Nations Secretary-General to serve on MAG of IGF – Express Healthcare
Dr Rajendra Pratap Gupta, a public policy leader, digital governance expert, AI researcher, and healthcare futurist,…
First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control
Phase 2 Study Results Highlight Use of Once-Daily Injection for Weight Loss and Reduction in Insulin…
Think Together Awards 2026 Beyond Think Together Scholarships to Ten High School Seniors Across the State
Each recipient received $3,000 to support their future higher education goals. SANTA ANA, Calif., June 5,…
Gounder Fills In Details Behind Ebola, GLP-1, and Trump Headlines – KFF Health News
Céline Gounder, KFF Health News’ editor-at-large for public health, discussed a recent study that suggests ultraprocessed…
Bio Preventive Medicine and Precision Diabetes Announce ADA Late-Breaking Presentation Highlighting DNlite™ in Landmark CREDENCE Trial
New analysis supports DNlite™ for earlier renal risk stratification in patients with type 2 diabetes and…
Novo Nordisk’s investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes–presented at ADA 2026
A phase 2 study of investigational once-weekly subcutaneous zenagamtide showed statistically significant reductions in blood sugar…